Matches in SemOpenAlex for { <https://semopenalex.org/work/W2617255666> ?p ?o ?g. }
- W2617255666 endingPage "2097" @default.
- W2617255666 startingPage "2097" @default.
- W2617255666 abstract "Acute isovolemic anemia occurs when blood loss is replaced with fluid. It is often observed after surgery and negatively influences short-term and long-term outcomes.To evaluate the efficacy and safety of ferric carboxymaltose to treat acute isovolemic anemia following gastrectomy.The FAIRY trial was a patient-blinded, randomized, phase 3, placebo-controlled, 12-week study conducted between February 4, 2013, and December 15, 2015, in 7 centers across the Republic of Korea. Patients with a serum hemoglobin level of 7 g/dL to less than 10 g/dL at 5 to 7 days following radical gastrectomy were included.Patients were randomized to receive a 1-time or 2-time injection of 500 mg or 1000 mg of ferric carboxymaltose according to body weight (ferric carboxymaltose group, 228 patients) or normal saline (placebo group, 226 patients).The primary end point was the number of hemoglobin responders, defined as a hemoglobin increase of 2 g/dL or more from baseline, a hemoglobin level of 11 g/dL or more, or both at week 12. Secondary end points included changes in hemoglobin, ferritin, and transferrin saturation levels over time, percentage of patients requiring alternative anemia management (oral iron, transfusion, or both), and quality of life at weeks 3 and 12.Among 454 patients who were randomized (mean age, 61.1 years; women, 54.8%; mean baseline hemoglobin level, 9.1 g/dL), 96.3% completed the trial. At week 12, the number of hemoglobin responders was significantly greater for ferric carboxymaltose vs placebo (92.2% [200 patients] for the ferric carboxymaltose group vs 54.0% [115 patients] for the placebo group; absolute difference, 38.2% [95% CI, 33.6%-42.8%]; P = .001). Compared with the placebo group, patients in the ferric carboxymaltose group experienced significantly greater improvements in serum ferritin level (week 12: 233.3 ng/mL for the ferric carboxymaltose group vs 53.4 ng/mL for the placebo group; absolute difference, 179.9 ng/mL [95% CI, 150.2-209.5]; P = .001) and transferrin saturation level (week 12: 35.0% for the ferric carboxymaltose group vs 19.3% for the placebo group; absolute difference, 15.7% [95% CI, 13.1%-18.3%]; P = .001); but there were no significant differences in quality of life. Patients in the ferric carboxymaltose group required less alternative anemia management than patients in the placebo group (1.4% for the ferric carboxymaltose group vs 6.9% for the placebo group; absolute difference, 5.5% [95% CI, 3.3%-7.6%]; P = .006). The total rate of adverse events was higher in the ferric carboxymaltose group (15 patients [6.8%], including injection site reactions [5 patients] and urticaria [5 patients]) than the placebo group (1 patient [0.4%]), but no severe adverse events were reported in either group.Among adults with isovolemic anemia following radical gastrectomy, the use of ferric carboxymaltose compared with placebo was more likely to result in improved hemoglobin response at 12 weeks.clinicaltrials.gov Identifier: NCT01725789." @default.
- W2617255666 created "2017-06-05" @default.
- W2617255666 creator A5001515388 @default.
- W2617255666 creator A5006193302 @default.
- W2617255666 creator A5013845955 @default.
- W2617255666 creator A5014592021 @default.
- W2617255666 creator A5016848883 @default.
- W2617255666 creator A5017366532 @default.
- W2617255666 creator A5018729289 @default.
- W2617255666 creator A5024069939 @default.
- W2617255666 creator A5024761792 @default.
- W2617255666 creator A5028131174 @default.
- W2617255666 creator A5028892367 @default.
- W2617255666 creator A5030930195 @default.
- W2617255666 creator A5034764661 @default.
- W2617255666 creator A5044912860 @default.
- W2617255666 creator A5047481009 @default.
- W2617255666 creator A5057610578 @default.
- W2617255666 creator A5066708574 @default.
- W2617255666 creator A5069167592 @default.
- W2617255666 creator A5071947672 @default.
- W2617255666 creator A5072048377 @default.
- W2617255666 creator A5076132049 @default.
- W2617255666 creator A5076976432 @default.
- W2617255666 creator A5079140720 @default.
- W2617255666 creator A5082745588 @default.
- W2617255666 creator A5083051960 @default.
- W2617255666 creator A5085951853 @default.
- W2617255666 date "2017-05-23" @default.
- W2617255666 modified "2023-09-29" @default.
- W2617255666 title "Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients With Acute Isovolemic Anemia Following Gastrectomy" @default.
- W2617255666 cites W1969327058 @default.
- W2617255666 cites W1972669243 @default.
- W2617255666 cites W1977735232 @default.
- W2617255666 cites W1981476022 @default.
- W2617255666 cites W1982946927 @default.
- W2617255666 cites W2024159843 @default.
- W2617255666 cites W2028161433 @default.
- W2617255666 cites W2042824688 @default.
- W2617255666 cites W2051732513 @default.
- W2617255666 cites W2065234253 @default.
- W2617255666 cites W2100052982 @default.
- W2617255666 cites W2107921622 @default.
- W2617255666 cites W2116948290 @default.
- W2617255666 cites W2117734216 @default.
- W2617255666 cites W2127841934 @default.
- W2617255666 cites W2134122718 @default.
- W2617255666 cites W2164843330 @default.
- W2617255666 cites W3021753536 @default.
- W2617255666 cites W4241443957 @default.
- W2617255666 cites W53765564 @default.
- W2617255666 cites W76459356 @default.
- W2617255666 doi "https://doi.org/10.1001/jama.2017.5703" @default.
- W2617255666 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5815040" @default.
- W2617255666 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28535237" @default.
- W2617255666 hasPublicationYear "2017" @default.
- W2617255666 type Work @default.
- W2617255666 sameAs 2617255666 @default.
- W2617255666 citedByCount "65" @default.
- W2617255666 countsByYear W26172556662017 @default.
- W2617255666 countsByYear W26172556662018 @default.
- W2617255666 countsByYear W26172556662019 @default.
- W2617255666 countsByYear W26172556662020 @default.
- W2617255666 countsByYear W26172556662021 @default.
- W2617255666 countsByYear W26172556662022 @default.
- W2617255666 countsByYear W26172556662023 @default.
- W2617255666 crossrefType "journal-article" @default.
- W2617255666 hasAuthorship W2617255666A5001515388 @default.
- W2617255666 hasAuthorship W2617255666A5006193302 @default.
- W2617255666 hasAuthorship W2617255666A5013845955 @default.
- W2617255666 hasAuthorship W2617255666A5014592021 @default.
- W2617255666 hasAuthorship W2617255666A5016848883 @default.
- W2617255666 hasAuthorship W2617255666A5017366532 @default.
- W2617255666 hasAuthorship W2617255666A5018729289 @default.
- W2617255666 hasAuthorship W2617255666A5024069939 @default.
- W2617255666 hasAuthorship W2617255666A5024761792 @default.
- W2617255666 hasAuthorship W2617255666A5028131174 @default.
- W2617255666 hasAuthorship W2617255666A5028892367 @default.
- W2617255666 hasAuthorship W2617255666A5030930195 @default.
- W2617255666 hasAuthorship W2617255666A5034764661 @default.
- W2617255666 hasAuthorship W2617255666A5044912860 @default.
- W2617255666 hasAuthorship W2617255666A5047481009 @default.
- W2617255666 hasAuthorship W2617255666A5057610578 @default.
- W2617255666 hasAuthorship W2617255666A5066708574 @default.
- W2617255666 hasAuthorship W2617255666A5069167592 @default.
- W2617255666 hasAuthorship W2617255666A5071947672 @default.
- W2617255666 hasAuthorship W2617255666A5072048377 @default.
- W2617255666 hasAuthorship W2617255666A5076132049 @default.
- W2617255666 hasAuthorship W2617255666A5076976432 @default.
- W2617255666 hasAuthorship W2617255666A5079140720 @default.
- W2617255666 hasAuthorship W2617255666A5082745588 @default.
- W2617255666 hasAuthorship W2617255666A5083051960 @default.
- W2617255666 hasAuthorship W2617255666A5085951853 @default.
- W2617255666 hasBestOaLocation W26172556662 @default.
- W2617255666 hasConcept C126322002 @default.
- W2617255666 hasConcept C141071460 @default.
- W2617255666 hasConcept C142724271 @default.
- W2617255666 hasConcept C153852466 @default.